Please login to the form below

axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

Novartis gets speedy reviews for new Kymriah filings

light from the FDA and EMA last year for its Yescarta (axicabtagene ciloleucel) therapy for adults with various types of B-cell lymphoma, including relapsed or refractory DLBCL.

Latest news

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Interest in CAR-T therapies in particular has been growing since the first two products in the category - Novartis’Kymriah (tisagenleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) - were approved for
Gilead adds to CAR-T assets with Cell Design Labs buyout

CAR-T is still considered to be in its infancy with Kite bringing the second therapy to market - Yescarta (axicabtagene ciloleucel) for relapsed or refractory B-cell lymphoma - shortly after
CAR-T therapies show long-term benefits in lymphoma

One-year results from the ZUMA-1 trial of Gilead’s Yescarta (axicabtagene ciloleucel) in aggressive non-Hodgkin’s lymphoma, plus six-month data from the JULIET trial of Novartis’Kymriah
Novartis files CAR-T therapy CTL109 in Europe

CAR-T Yescarta (axicabtagene ciloleucel) in relapsed/refractory B cell lymphoma.
Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

its Yescarta (axicabtagene ciloleucel) in relapsed/refractory B cell lymphoma earlier last week.

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Great salary and benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Project Manager, Medical Communications, London: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Scientific Director: Great salary and bebefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager – Med Comms – Kent: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Medical Writer, e-learning/ training, London: Excellent Salary

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...